DK2908836T3 - Farmaceutisk formulering indeholdende curcuma - Google Patents

Farmaceutisk formulering indeholdende curcuma Download PDF

Info

Publication number
DK2908836T3
DK2908836T3 DK13740296.2T DK13740296T DK2908836T3 DK 2908836 T3 DK2908836 T3 DK 2908836T3 DK 13740296 T DK13740296 T DK 13740296T DK 2908836 T3 DK2908836 T3 DK 2908836T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical formulation
formulation containing
containing curcuma
curcuma
pharmaceutical
Prior art date
Application number
DK13740296.2T
Other languages
English (en)
Inventor
Uwe-Bernd Rose
Original Assignee
Briu Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Briu Gmbh filed Critical Briu Gmbh
Application granted granted Critical
Publication of DK2908836T3 publication Critical patent/DK2908836T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L31/00—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof
    • H01L31/04—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof adapted as photovoltaic [PV] conversion devices
    • H01L31/042—PV modules or arrays of single PV cells
    • H01L31/05—Electrical interconnection means between PV cells inside the PV module, e.g. series connection of PV cells
    • H01L31/0504—Electrical interconnection means between PV cells inside the PV module, e.g. series connection of PV cells specially adapted for series or parallel connection of solar cells in a module
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L31/00—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof
    • H01L31/04—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof adapted as photovoltaic [PV] conversion devices
    • H01L31/042—PV modules or arrays of single PV cells
    • H01L31/05—Electrical interconnection means between PV cells inside the PV module, e.g. series connection of PV cells
    • H01L31/0504—Electrical interconnection means between PV cells inside the PV module, e.g. series connection of PV cells specially adapted for series or parallel connection of solar cells in a module
    • H01L31/0508—Electrical interconnection means between PV cells inside the PV module, e.g. series connection of PV cells specially adapted for series or parallel connection of solar cells in a module the interconnection means having a particular shape
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L31/00—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof
    • H01L31/04—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof adapted as photovoltaic [PV] conversion devices
    • H01L31/054—Optical elements directly associated or integrated with the PV cell, e.g. light-reflecting means or light-concentrating means
    • H01L31/0547—Optical elements directly associated or integrated with the PV cell, e.g. light-reflecting means or light-concentrating means comprising light concentrating means of the reflecting type, e.g. parabolic mirrors, concentrators using total internal reflection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/50—Photovoltaic [PV] energy
    • Y02E10/52—PV systems with concentrators
DK13740296.2T 2012-10-22 2013-07-24 Farmaceutisk formulering indeholdende curcuma DK2908836T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012219219.0A DE102012219219A1 (de) 2012-10-22 2012-10-22 Pharmazeutische Formulierung enthaltend Curcumin
PCT/EP2013/065661 WO2014063844A1 (de) 2012-10-22 2013-07-24 Pharmazeutische formulierung enthaltend curcumin

Publications (1)

Publication Number Publication Date
DK2908836T3 true DK2908836T3 (da) 2019-12-16

Family

ID=48874303

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13740296.2T DK2908836T3 (da) 2012-10-22 2013-07-24 Farmaceutisk formulering indeholdende curcuma

Country Status (14)

Country Link
US (1) US11382871B2 (da)
EP (1) EP2908836B1 (da)
CY (1) CY1122694T1 (da)
DE (2) DE202012013584U1 (da)
DK (1) DK2908836T3 (da)
ES (1) ES2759621T3 (da)
HR (1) HRP20192208T1 (da)
HU (1) HUE046492T2 (da)
LT (1) LT2908836T (da)
PL (1) PL2908836T3 (da)
PT (1) PT2908836T (da)
RS (1) RS59631B1 (da)
SI (1) SI2908836T1 (da)
WO (1) WO2014063844A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660967B2 (en) 2016-10-21 2020-05-26 Augusta University Research Institute, Inc. Curcumin conjugates and methods of use thereof
EP3275430B1 (de) 2017-04-07 2023-06-21 Rohan Charles Fernando Curcuminlösung zur intravenösen infusion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669918C (en) * 2006-11-15 2020-03-10 Arthritis Relief Plus Ltd Topical formulation comprising comfrey and tannic acid, and uses thereof
US20100197584A1 (en) * 2007-07-27 2010-08-05 Research Foundations of the City University of- New York Use of curcumin to block brain tumor formation in mice
CN101138550B (zh) 2007-09-18 2012-06-27 沈阳药科大学 多种表面活性剂联合使用制备的混合胶束药物制剂及其制备方法
KR20090047637A (ko) 2007-11-08 2009-05-13 재단법인서울대학교산학협력재단 커큐민 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 통증 예방 및 치료용 조성물
WO2010010431A1 (en) 2008-07-24 2010-01-28 National Institute Of Pharmaceutical Education And Research Self-nano-emulsifying curcuminoids composition with enhanced bioavailability
CN101548946B (zh) * 2009-02-17 2012-04-25 海口市制药厂有限公司 姜黄素纳米脂质注射液、其制备方法及用途
IT1395086B1 (it) 2009-03-11 2012-09-05 Velleja Res Srl Composizioni comprendenti curcumina in forma complessata con fosfolipidi e piperina ad azione chemio-sensibilizzante
WO2011101859A1 (en) 2010-02-22 2011-08-25 Institute Of Life Sciences A novel water soluble curcumin loaded nanoparticulate system for cancer therapy
EP2616053B1 (en) 2010-09-15 2016-11-02 Cadila Pharmaceuticals Ltd. Pharmaceutical compositions of curcumin
CN102225048A (zh) * 2011-04-27 2011-10-26 中国人民解放军第二军医大学 一种姜黄素类化合物注射溶液及其静脉注射剂
CN102670574A (zh) * 2012-05-15 2012-09-19 中国人民解放军总医院 姜黄素在制备治疗肠缺血再灌注损伤药物中的应用

Also Published As

Publication number Publication date
DE202012013584U1 (de) 2018-01-15
CY1122694T1 (el) 2021-03-12
LT2908836T (lt) 2020-01-27
PT2908836T (pt) 2019-12-16
PL2908836T3 (pl) 2020-06-15
ES2759621T3 (es) 2020-05-11
SI2908836T1 (sl) 2020-02-28
EP2908836A1 (de) 2015-08-26
DE102012219219A1 (de) 2014-05-28
EP2908836B1 (de) 2019-09-11
RS59631B1 (sr) 2020-01-31
HUE046492T2 (hu) 2020-03-30
US11382871B2 (en) 2022-07-12
US20150342904A1 (en) 2015-12-03
HRP20192208T1 (hr) 2020-02-21
WO2014063844A1 (de) 2014-05-01

Similar Documents

Publication Publication Date Title
HK1211209A1 (en) Pharmaceutical formulation containing thienotriazolodiazepine compounds
DK3181122T3 (da) Farmaceutisk dasatinib-sammensætning
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
BR112015002738A2 (pt) composto , e , composição farmacêutica
DK2897594T3 (da) Farmaceutisk sammensætning
CO6940426A2 (es) Formulaciones farmacéuticas
DK2815752T3 (da) Oral farmaceutisk sammensætning
CL2014003283A1 (es) Formulación farmacéutica.
DK2502622T3 (da) Farmaceutisk formulering omfattende inositol
BR112015003116A2 (pt) preparação farmacêutica sólida contendo levotiroxina
HK1205683A1 (en) Pharmaceutical formulation having improved stability
DK3473255T3 (da) Farmaceutisk formulering omfattende ciclesonid
CO7091176A2 (es) Diagnóstico farmacéutico
BR112015002646A2 (pt) composto e composição farmacêutica
DK2919761T3 (da) Fast doseringsform omfattende mikroniseret cytisin
SMT201600419B (it) Composizione farmaceutica contenente fosfolipidi
DK2908836T3 (da) Farmaceutisk formulering indeholdende curcuma
HK1206269A1 (en) Pharmaceutical formulation comprising bendamustine
HK1204945A1 (en) Pharmaceutical formulation containing flupirtin
HK1209339A1 (en) Pharmaceutical formulations
ECSP12011630A (es) Formulación farmacéutica
TH148806B (th) สูตรผสมทางเภสัชกรรมที่มีความคงตัวดีขึ้น
TH1301004215B (th) องค์ประกอบเชิงเภสัชกรรมซึ่งประกอบรวมด้วยอนุพันธ์ไพริโอน
BR112015003211A8 (pt) compostos farmacêuticos de memantina
GB201211406D0 (en) Pharmaceutical formulations